This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
CORTNegative Net Change TRDAPositive Net Change ZVRANegative Net Change
biotechnology biotechs medical pharmaceuticals
uniQure (QURE) Soars on New Huntington's Disease Study Data
by Zacks Equity Research
uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.
CGENPositive Net Change QUREPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
by Zacks Equity Research
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
ADPTPositive Net Change RAPTPositive Net Change ATHAPositive Net Change ACRVPositive Net Change
biotechs
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
by Zacks Equity Research
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
CGENPositive Net Change IDYAPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
by Zacks Equity Research
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
by Zacks Equity Research
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
AVXLNegative Net Change MIRMPositive Net Change RAPTPositive Net Change ACRVPositive Net Change
biotechs
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
by Zacks Equity Research
HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.
AVXLNegative Net Change RAPTPositive Net Change HLVXNegative Net Change ACRVPositive Net Change
biotechs
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
by Zacks Equity Research
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
SNYPositive Net Change ADMAPositive Net Change KYMRPositive Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
ACETPositive Net Change CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
RHHBYPositive Net Change PFEPositive Net Change SRPTPositive Net Change RGNXPositive Net Change SLDBPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
by Zacks Equity Research
The recent label expansion of Mirum's (MIRM) lead drug, Livmarli, is expected to drive sales in the upcoming quarters. The company's efforts to build its pipeline beyond Livmarli also hold promise.
MIRMPositive Net Change RAPTPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
by Zacks Equity Research
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
CGENPositive Net Change IMVTPositive Net Change ALXOPositive Net Change DNTHPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
by Ekta Bagri
While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.
GSKPositive Net Change GILDNegative Net Change MRUSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
by Zacks Equity Research
Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.
CGENPositive Net Change APLSPositive Net Change ALXOPositive Net Change ALGSPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
by Zacks Equity Research
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSKPositive Net Change RAPTPositive Net Change CVACPositive Net Change ALGSPositive Net Change
biotechs
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
RHHBYPositive Net Change MRKPositive Net Change CGENPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
GSKPositive Net Change MRNAPositive Net Change RCKTNegative Net Change CVACPositive Net Change RNACPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
NERVPositive Net Change ARGXNegative Net Change ALXOPositive Net Change RNACPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
MRNAPositive Net Change NVAXPositive Net Change CVACPositive Net Change
biotechs medical messenger-rna vaccines
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
by Zacks Equity Research
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
VRTXNegative Net Change RAPTPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
by Zacks Equity Research
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change ALGSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
REGNNegative Net Change SNYPositive Net Change NERVPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
by Zacks Equity Research
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
RAPTPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechs medical pharmaceuticals